Comparing Medications for Reducing Kidney Damage in Diabetes: A Study on Dapagliflozin Alone and with Eplerenone
Phase 4
- Conditions
- Health Condition 1: E08-E13- Diabetes mellitus
- Registration Number
- CTRI/2024/01/061952
- Lead Sponsor
- Dr Nikhil Kumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
b)Patients having urinary albumin to creatinine ratio (UACR) more than >30mg/mmol.
Exclusion Criteria
a)Failure to give consent
b)History of serious reactions to dapagliflozin and eplerenone
c)Severe renal impairment (eGfr less than 30/ml/min/1.73m2
d)End-stage renal disease (ESRD)
e)Patient on dialysis
f)Patient having serum potassium >5.5meq/l at initiation
g)Concomitant administration of strong cyp3a inhibitors (e.g. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir
h)Concomitant administration of potassium supplements or potassium-sparing diuretics
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method